Home / Products / Inhibitors / PI3K Inhibitor / 915019-65-7


Cat.No.ABP000081 Chemical NameBEZ235/NVP-BEZ235/BE-Z235/ MolFormulaC30H23N5O MolWeight469.5365 Purity 99%

Chemical Name : BEZ235/NVP-BEZ235/BE-Z235/

CAS : 915019-65-7

Synonyms: 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile


Storage:-20C 2 years


Orally active PI3K tyrosine kinase inhibitor; Dual PI3K/mTOR inhibition; BEZ235 showed high target specificity and demonstrated antiproliferative activity against tumor cell lines in animal models of cancer.

NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells. The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status. The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235


1. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P.J.A., Valero, V., Guzman, M., Botero, M.L., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. 2008 Cancer Research 68 (19), pp. 8022-8030

2. ichhorn, P.J.A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R.L., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. 2008 Cancer Research 68 (22), pp. 9221-9230